Research programme: ALK2 inhibitors - BioCryst Pharmaceuticals

Drug Profile

Research programme: ALK2 inhibitors - BioCryst Pharmaceuticals

Alternative Names: BCX 9250; BCX 9499

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioCryst Pharmaceuticals
  • Class
  • Mechanism of Action ACVR1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fibrodysplasia ossificans progressiva

Most Recent Events

  • 27 Feb 2018 BioCryst Pharmaceuticals plans to file an IND application with the US FDA for Fibrodysplasia ossificans progressiva
  • 05 Jan 2018 Preclinical trials in Fibrodysplasia ossificans progressiva in USA (PO)
  • 05 Jan 2018 BioCryst plans a phase I trial for Fibrodysplasia ossificans progressiva in USA in the first half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top